GENERAL16 Sept 2026
Fortis Healthcare shares outlook by Nomura: Rating neutral and target price remains ₹1030 - check rationale | Stock Market News
Nomura has kept its 'neutral' rating on Fortis Healthcare with a ₹1,030 target price, even as the stock fell about 6% in a month. It says growth is already priced in and margins face employee stock option (ESOP) costs and wage pressure. June quarter profit rose 2.3% to ₹273 crore. For now, expect limited upside. Track the forensic audit news before investing.
Key Statutory Highlights
- Nomura kept a 'neutral' rating on Fortis Healthcare with a target price of ₹1,030 per share.
- Fortis shares fell 4.61% in a week, 6.04% in a month, and are down 3.08% so far in 2026.
- IHH plans to raise its stake in Fortis to 51% from 31.2% over three to five years and merge Gleneagles India with Fortis at the right time.
Actionable Advice for Taxpayers / Founders:If you hold or plan to buy Fortis shares, treat this as one broker's view only, check the company's forensic audit updates, and speak to a SEBI-registered adviser before acting.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: